Fabry disease: Preclinical studies demonstrate the effectiveness of α-galactosidase a replacement in enzyme-deficient mice

American Journal of Human Genetics

Volumn 68, Issue 1, 2001, Pages 14-25

  Ioannou, Yiannis A ^a   Zeidner, Ken M ^a   Gordon, Robert E ^a   Desnick, Robert J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; GLOBOTRIAOSYLCERAMIDE; MANNOSE 6 PHOSPHATE; RECOMBINANT ENZYME; SIALIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG LIVER LEVEL; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME REPLACEMENT; FABRY DISEASE; MOUSE; NONHUMAN; PHARMACODYNAMICS; PLASMA HALF LIFE; PRIORITY JOURNAL; TISSUE DISTRIBUTION; ULTRASTRUCTURE;

EID: 0035163539     PISSN: 00029297     EISSN: None     Source Type: Journal    
DOI: 10.1086/316953     Document Type: Article

References (39)

1. Human beta-glucuronidase: In vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells
2. Hepatic catabolism of low density lipoprotein: Mechanisms and metabolic consequences
3. The effect of phlebotomy as a treatment of Fabry disease
4. Quantitative analysis of the targeting of mannose-terminal glucocerebrosidase
5. Human α-galactosidase A: Nucleotide sequence of a cDNA clone encoding the mature enzyme
6. Purification and characterization of human α-galactosidase isozymes: Comparison of tissue and plasma forms and evaluation of purification methods
7. Enzyme therapy. XX. Further evidence for the differential in vivo fate of human splenic and plasma forms of α-galactosidase A in Fabry disease: Recovery of exogenous activity from hepatic tissue
8. Fluorometric assay of protein in the nanogram range
9. Verotoxin receptor glycolipid in human renal tissue
10. Replacement therapy for inherited enzyme deficiency: Use of purified ceramidetrihexosidase in Fabry's disease
11. Glycosphingolipids and plasma lipoproteins: A review
12. Angiokeratoma corporis diffusum - Fabry's disease
13. Fabry's disease: Enzymatic diagnosis of hemizygotes and heterozygotes: α-galactosidase activities in plasma, serum, urine, and leukocytes
14. Enzyme therapy in Fabry disease: Differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic α-galactosidase A isozymes
15. Enzyme therapy. XVII. Metabolic and immunologic evaluation of α-galactosidase A replacement in Fabry disease
16. α-galactosidase A deficiency: Fabry disease
17. α-Galactosidase A deficiency: Fabry disease
18. Receptor-mediated endocytosis of galactose and mannose exposing ligands: An electron microscopic study on adult and neonatal cultured rat hepatocytes
19. Enzyme replacement therapy in Fabry disease: Results of a placebo-controlled phase 3 trial
20. Enzyme replacement therapy in Fabry diseases: Results of a phase I/II clinical trial
21. Enzyme therapy. VIII. Immunologic evaluation of repeated administration of erythrocyte-entrapped β-glucuronidase to β-glucuronidase deficient mice
22. Lipid composition of lysosomal multilamellar bodies in male mouse urine
23. Overexpression of human α-galactosidase A results in its intracellular aggregation, crystallization in lysosomes and selective secretion
24. Human α-galactosidase A: Glycosylation site 3 is essential for enzyme solubility
25. Hepatic endocytosis of various types of mannose-terminated albumins: What is important, sugar recognition, net charge, or the combination of these features
26. Plasmapheresis therapy for the lipidoses
27. Quantitative high-performance thin-layer chromatography of lipids in plasma and liver homogenates after direct application of 0.5-microliter samples to the silica-gel layer
28. Proliferin secreted by cultured cells binds to mannose-6-phosphate receptors
29. Ten-year experience in renal transplantation for Fabry's disease
30. Enzyme replacement as a possible therapy for Fabry's disease
31. Human α-galactosidase A: Characterization of the N-linked oligosaccharides on the intracellular and secreted glycoforms overexpressed by Chinese hamster ovary cells
32. Testosterone-responsive mouse kidney glycosphingolipids: Developmental and inbred strain effects
33. Testosterone effects on the induction and urinary excretion of mouse kidney glycosphingolipids associated with lysosomes
34. M2 gangliosidosis: Organ deposition and induced central nervous system uptake of β-hexosaminidase in the cat
35. Efficacy and safety of enzyme replacement therapy for Fabry disease demonstrated by a double-blind placebo-controlled trial
36. Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease
37. Generation of a mouse model with α-galactosidase A deficiency
38. Tissue-specific alternative splicing of the beta-galactoside alpha 2, 6-sialyl-transferase gene
39. Quantitative determination of globotriaosylceramide by immunodetection of glycolipid-bound recombinant verotoxin B subunit